tiprankstipranks
Iovance Biotherapeutics Inc (IOVA)
NASDAQ:IOVA
Holding IOVA?
Track your performance easily

Iovance Biotherapeutics (IOVA) Ownership - Who Owns Iovance Biotherapeutics?

2,996 Followers

Iovance Biotherapeutics (IOVA) Ownership Overview

9.58%14.95%36.50%16.84%22.14%
36.50% Other Institutional Investors
16.84% ETFs
22.14% Public Companies and Individual Investors
The ownership structure of Iovance Biotherapeutics (IOVA) stock is a mix of institutional, retail, and individual investors. Approximately 68.28% of the company’s stock is owned by Institutional Investors, 9.58% is owned by Insiders, and 22.14% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Nov 14, 2024
Ryan Maynard
Director
xxxxxxxxxxxxx
$503000
Feb 20, 2024
xxxxxxxxxxxxx
$292800
Feb 20, 2024
xxxxxxxxxxxxx
$45750000
Feb 20, 2024
xxxxxxxxxxxxx
$2287500

Recent Hedge Fund Trading Activity

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
28,067,333Insider9.21%231,274,824
26,617,709Institution8.73%219,329,922
25,777,876Institution8.46%212,409,698
22,239,865Institution7.30%183,256,488
12,510,693Institution4.10%103,088,110
7,682,529Institution2.52%63,304,039
2,920,334Institution0.96%24,063,552
2,563,567Institution0.84%21,123,792
2,423,725Institution0.80%19,971,494
1,595,062Institution0.52%13,143,311

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
22,239,865Institution7.30%183,256,488
2,920,334Institution0.96%24,063,552
2,563,567Institution0.84%21,123,792
2,423,725Institution0.80%19,971,494
1,595,062Institution0.52%13,143,311
1,408,584Institution0.46%11,606,732
1,285,209Institution0.42%10,590,122
1,279,288Institution0.42%10,541,333
1,107,215Institution0.36%9,123,452
993,377Institution0.33%8,185,426

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
8,671,292Institution2.85%90,528,288
6,844,849Institution2.25%71,460,224
6,880,523Institution2.26%56,695,510
6,938,104Institution2.28%56,476,167
4,628,737Institution1.52%48,324,014
3,361,245Institution1.10%35,091,398
2,279,564Institution0.75%18,783,607
1,689,720Institution0.55%13,923,293
1,154,011Institution0.38%12,047,875
1,089,249Institution0.36%8,866,487

FAQ

Who Owns Iovance Biotherapeutics Inc (IOVA)?
According to the latest TipRanks data, approximately 36.50% of the company's stock is held by institutional investors, 9.58% is held by insiders, and 22.14% is held by retail investors.
    What percentage of Iovance Biotherapeutics Inc (IOVA) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 36.50% of Iovance Biotherapeutics Inc (IOVA) stock is held by institutional investors.
      What percentage of Iovance Biotherapeutics Inc (IOVA) stock is held by retail investors?
      According to the latest TipRanks data, approximately 22.14% of Iovance Biotherapeutics Inc (IOVA) stock is held by retail investors.
        Who owns the most shares of Iovance Biotherapeutics Inc (IOVA)?
        Wayne P. Rothbaum owns the most shares of Iovance Biotherapeutics Inc (IOVA).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis